New pharma policy to be ready by Nov 27 as GoM hammers out ‘consensus’ over possible pricing formula
Pushed by the Supreme Court to finalise the National Pharmaceutical Pricing Policy before November 27, the Group of Ministers (GoM) on Wednesday claimed to have settled the differences among the key ministries over the pricing mechanism and vowed to announce the policy in time.
Pushed by the Supreme Court to finalise the National Pharmaceutical Pricing Policy before November 27, the Group of Ministers (GoM) on Wednesday claimed to have settled the differences among the key ministries over the pricing mechanism and vowed to announce the policy in time.
However, the GoM headed by Agriculture Minister Sharad Pawar did not spell out the consensus formula.
“We had resolved all the issues. There were certain issues that were being raised by some of my colleagues. We discussed in-depth and we came to an agreeable formula. I think November 27 is the date when Supreme Court is going to take a view on this,” Pawar told reporters after the GoM meeting.
The GoM had earlier decided on weighted average price of drugs with over 1 per cent. However, the fate of the policy was again pushed into dilemma after Finance Minister P Chidmabaram expressed reservations over the pricing formula and called for existing model of cost-based mechanism.
The Finance Minister was a special invitee at the meet. Apart from Pawar, the group consisted of Commerce Minister Anand Sharma and Minister of State for Chemicals Srikant Jena, Health Minister Ghulam Nabi Azad, Minister for HRD, Communications and IT Kapil Sibal, External Affairs Minister Salman Khurshid and Planning Commission Deputy Chairman Montek Singh Ahluwalia.
Now, once the GoM's recommendations are finalised, it will be sent to the cabinet for approval. Before November 27, there will be a cabinet meeting where all these recommendations will be finalised and pharma policy will be given a final approval by the union cabinet. On November 27, the Supreme Court is slated to hear a Public Interest Litigation (PIL) that was filed on the pharma pricing policy.
Related News
-
News Introducing the Pharmaceutical Sustainability Ecosystem from CPHI
The Sustainability Collective from CPHI unveils the groundbreaking Pharmaceutical Sustainability Ecosystem to drive pharmaceutical knowledge sharing, connection, and collaboration in order to change the face of sustainability in pharmceutical... -
News US Government shutdown leads to the FDA grinding to a halt
The US Congress reached a deadlock after not being able to come to an agreement regarding funding, specifically reaching an impasse when Republicans and Democrats were unable to reach an agreement regarding Obamacare subsidies. The resulting shutdown o... -
News Biosimilars for the better: an expert view from Ecolab
Ecolab expert Renato Azevedo shares his insights on the current state of the biosimilars market in pharmaceuticals, after a high number of biosimilar drug approvals throughout the year confirming the shift of focus in this field. -
News US FDA announces new priority vouchers for accelerated review times
The US FDA announced a new priority program for drug developers – the Commissioner’s National Priority Voucher (CNPV) program aims to enhance the health interests of the US by allowing drug developers to redeem a voucher, shortening th... -
News CPHI Podcast Series: US drug policy – exploring the executive orders
The latest episode of the CPHI Podcast Series provides a timely overview of the recent policy changes in the USA, with President Trump signing excecutive orders to change drug pricing under a 'Most Favoured Nation' scheme.
-
News PhRMA trade association issues comments on Section 232 investigation
The Pharmaceutical Research and Manufacturers of America (PhRMA), an American trade association representing groups in the pharmaceutical industry, issued a letter on May 6, 2026 to the Department of Commerce regarding the Section 232 National Security... -
News Pharmaceutical Packaging Market Prospects: Shifting regional policies
The pharmaceutical packaging industry is experiencing significant transformation in 2025, driven by regulatory changes, supply chain challenges, and sustainability initiatives. The US BIOSECURE Act, passed through the House of Representatives in Septem... -
News The next 15 drugs up for negotiation with Medicare include several blockbusters
By now, everyone is quite familiar with the drug price negotiations taking place between drug companies and the Centres for Medicare & Medicaid Services (CMS) in the USA as part of measures being taken to reduce the cost of drugs for patients, to make ...